Filing Details
- Accession Number:
- 0001209191-18-017256
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-06 16:29:19
- Reporting Period:
- 2018-03-02
- Accepted Time:
- 2018-03-06 16:29:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-02 | 4,000 | $5.50 | 28,905 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-02 | 2,000 | $200.60 | 26,905 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-02 | 1,700 | $201.68 | 25,205 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-02 | 300 | $202.32 | 24,905 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-03-02 | 4,000 | $0.00 | 4,000 | $5.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 63,951 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- The range in prices for the transaction reported on this line was $200.00 to $200.85. The average weighted price was $200.6006. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $201.15 to $202.10. The average weighted price was $201.6793. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $202.25 to $202.35. The average weighted price was $202.3167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of April 1, 2013 and May 1, 2013. The shares underlying these options vested as follows: 25% vested on April 1, 2014 and May 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years.
Billionaire Hedge Funds
